During the AcrySof® ReSTOR® IOL clinical studies, patients' lifestyles were enhanced through improved vision and greater freedom from reading glasses and bifocals. In fact, according to the AcrySof® ReSTOR® IOL clinical studies, 80% of AcrySof® ReSTOR® IOL patients found they no longer depended upon their glasses, compared to only 8% of patients with monofocal lenses following bilateral cataract surgery.
Additionally, the AcrySof® ReSTOR® IOL clinical studies indicated that nearly 94% of the study subjects were so satisfied with their improved vision that they would have the AcrySof® ReSTOR® IOL implanted again.
Clinical studies with the AcrySof® ReSTOR® IOL as compared to a monofocal control demonstrated:
Copyright © 2012 Novartis AG a global company based in Basel, Switzerland. The information and materials within this section pertain to the U.K. market only. Not all products are approved in every marked and approved labeling and instructions may vary by local country. See the Alcon Privacy Policy and Terms & Conditions for the use of this site.